Tramuto F, Maida C, Randazzo G, Guzzetta V, Santino A, Li Muli R
Viruses. 2024; 16(6).
PMID: 38932144
PMC: 11209242.
DOI: 10.3390/v16060851.
Gao R, Sreenivasan C, Sheng Z, Hause B, Zhou B, Wentworth D
J Virol. 2020; 94(22).
PMID: 32847862
PMC: 7592206.
DOI: 10.1128/JVI.00945-20.
Joyce M, Bao A, Chen M, Georgiev I, Ou L, Bylund T
Pathog Immun. 2020; 4(2):294-323.
PMID: 31893251
PMC: 6922093.
DOI: 10.20411/pai.v4i2.338.
Tang A, Chen Z, Cox K, Su H, Callahan C, Fridman A
Nat Commun. 2019; 10(1):4153.
PMID: 31515478
PMC: 6742648.
DOI: 10.1038/s41467-019-12137-1.
Abou-El-Hassan H, Massaad E, Soudani N, Assaf-Casals A, Shaker R, Lteif Khoury M
PLoS One. 2019; 14(2):e0212687.
PMID: 30789963
PMC: 6383889.
DOI: 10.1371/journal.pone.0212687.
Sequence Analysis of the Fusion Protein Gene of Human Respiratory Syncytial Virus Circulating in China from 2003 to 2014.
Song J, Wang H, Ng T, Cui A, Zhu S, Huang Y
Sci Rep. 2018; 8(1):17618.
PMID: 30514963
PMC: 6279739.
DOI: 10.1038/s41598-018-35894-3.
Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset.
Mas V, Nair H, Campbell H, Melero J, Williams T
Vaccine. 2018; 36(45):6660-6673.
PMID: 30292456
PMC: 6203811.
DOI: 10.1016/j.vaccine.2018.09.056.
Neutralizing epitopes of RSV and palivizumab resistance in Japan.
Hashimoto K, Hosoya M
Fukushima J Med Sci. 2017; 63(3):127-134.
PMID: 28867684
PMC: 5792496.
DOI: 10.5387/fms.2017-09.
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa J, Sauer M, Sevy A, Finn J, Bates J, Alvarado G
Proc Natl Acad Sci U S A. 2016; 113(44):E6849-E6858.
PMID: 27791117
PMC: 5098655.
DOI: 10.1073/pnas.1609449113.
Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.
Palomo C, Mas V, Detalle L, Depla E, Cano O, Vazquez M
Antimicrob Agents Chemother. 2016; 60(11):6498-6509.
PMID: 27550346
PMC: 5075053.
DOI: 10.1128/AAC.00842-16.
Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.
Oliveira D, Iwane M, Prill M, Weinberg G, Williams J, Griffin M
J Clin Virol. 2015; 65:26-31.
PMID: 25766983
PMC: 7172275.
DOI: 10.1016/j.jcv.2015.01.016.
Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.
Bates J, Keefer C, Slaughter J, Kulp D, Schief W, Crowe Jr J
Virology. 2014; 454-455:139-44.
PMID: 24725940
PMC: 4004766.
DOI: 10.1016/j.virol.2014.02.010.
Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.
Kumari S, Crim R, Kulkarni A, Audet S, Mdluli T, Murata H
Clin Vaccine Immunol. 2014; 21(3):383-90.
PMID: 24403526
PMC: 3957679.
DOI: 10.1128/CVI.00594-13.
Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.
Melero J, Moore M
Curr Top Microbiol Immunol. 2013; 372:59-82.
PMID: 24362684
PMC: 4880365.
DOI: 10.1007/978-3-642-38919-1_3.
Gold nanorod vaccine for respiratory syncytial virus.
Stone J, Thornburg N, Blum D, Kuhn S, Wright D, Crowe Jr J
Nanotechnology. 2013; 24(29):295102.
PMID: 23799651
PMC: 3754908.
DOI: 10.1088/0957-4484/24/29/295102.
Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.
Bates J, Keefer C, Utley T, Correia B, Schief W, Crowe Jr J
J Immunol. 2013; 190(7):3732-9.
PMID: 23455501
PMC: 3608519.
DOI: 10.4049/jimmunol.1202964.
Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010.
Papenburg J, Carbonneau J, Hamelin M, Isabel S, Bouhy X, Ohoumanne N
Emerg Infect Dis. 2012; 18(1):120-4.
PMID: 22264682
PMC: 3310097.
DOI: 10.3201/eid1801.110515.
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
Swanson K, Settembre E, Shaw C, Dey A, Rappuoli R, Mandl C
Proc Natl Acad Sci U S A. 2011; 108(23):9619-24.
PMID: 21586636
PMC: 3111287.
DOI: 10.1073/pnas.1106536108.
Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.
Hultberg A, Temperton N, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B
PLoS One. 2011; 6(4):e17665.
PMID: 21483777
PMC: 3069976.
DOI: 10.1371/journal.pone.0017665.
Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years.
Yang C, Wang C, Tollefson S, Piyaratna R, Lintao L, Chu M
Virol J. 2009; 6:138.
PMID: 19740442
PMC: 2753315.
DOI: 10.1186/1743-422X-6-138.
